The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-06

AUTHORS

Christophe Legendre, Stephen M. Beard, Anne Crochard, Yvon Lebranchu, Claire Pouteil-Noble, Anke Richter, Isabelle Durand-Zaleski

ABSTRACT

Prophylaxis-based antiviral treatment and intensive monitoring followed by pre-emptive antiviral treatment are both commonly used management strategies to reduce risk of cytomegalovirus (CMV) infection following renal transplantation. This study employed a decision-model approach using published efficacy data and information from a recent survey of French clinical practice to consider the relative costs and outcomes associated with CMV prevention strategies for high-risk patient groups. The cost per case of treating tissue invasive and symptomatic CMV disease was estimated at €15,431 and €10,852, respectively. In the highest infection-risk patient group (positive donor with no previous CMV history) prophylactic oral valaciclovir was shown to avoid the greatest number of CMV disease cases (35 cases per 100 transplanted patients) and reduced the overall CMV-related costs per transplanted patient by around 14% over a ‘wait-and-treat’ baseline strategy. In contrast, intensive monitoring and pre-emptive treatment resulted in a much higher cost per transplanted patient. This analysis suggests that prophylactic treatment remains the most cost-effective approach to the management of CMV in renal-transplanted patients. Further comparative studies between prophylactic and pre-emptive treatment would be a valuable addition to the current evidence based on CMV prevention. More... »

PAGES

172-182

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10198-004-0275-9

DOI

http://dx.doi.org/10.1007/s10198-004-0275-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1022923673

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15765243


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Acyclovir", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiviral Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytomegalovirus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytomegalovirus Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunocompromised Host", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Valacyclovir", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Valine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "St. Louis Hospital, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.413328.f", 
          "name": [
            "St. Louis Hospital, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Legendre", 
        "givenName": "Christophe", 
        "id": "sg:person.07562422057.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07562422057.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "RTI Health Solutions, Williams House, Manchester Science Park, Lloyd Street North, M15\u00a06SE, Manchester, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "RTI Health Solutions, Manchester, UK", 
            "RTI Health Solutions, Williams House, Manchester Science Park, Lloyd Street North, M15\u00a06SE, Manchester, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Beard", 
        "givenName": "Stephen M.", 
        "id": "sg:person.01237500524.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237500524.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline, Marly le Roi, France", 
          "id": "http://www.grid.ac/institutes/grid.476503.3", 
          "name": [
            "GlaxoSmithKline, Marly le Roi, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Crochard", 
        "givenName": "Anne", 
        "id": "sg:person.0626017540.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626017540.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bretonneau Hospital, Tours, France", 
          "id": "http://www.grid.ac/institutes/grid.411777.3", 
          "name": [
            "Bretonneau Hospital, Tours, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lebranchu", 
        "givenName": "Yvon", 
        "id": "sg:person.01075026142.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075026142.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Lyon-Sud Hospital, Pierre-Benite, France", 
          "id": "http://www.grid.ac/institutes/grid.411430.3", 
          "name": [
            "Lyon-Sud Hospital, Pierre-Benite, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pouteil-Noble", 
        "givenName": "Claire", 
        "id": "sg:person.01217563561.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217563561.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "RTI Health Solutions, Research Triangle Park, N.C., USA", 
          "id": "http://www.grid.ac/institutes/grid.416262.5", 
          "name": [
            "RTI Health Solutions, Research Triangle Park, N.C., USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Richter", 
        "givenName": "Anke", 
        "id": "sg:person.0677521431.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0677521431.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "ANAES, St. Denis la Plaine, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "ANAES, St. Denis la Plaine, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Durand-Zaleski", 
        "givenName": "Isabelle", 
        "id": "sg:person.01327533357.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327533357.46"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.2165/00019053-200018030-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028894956", 
          "https://doi.org/10.2165/00019053-200018030-00004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-200321070-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008090922", 
          "https://doi.org/10.2165/00019053-200321070-00002"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-06", 
    "datePublishedReg": "2005-06-01", 
    "description": "Prophylaxis-based antiviral treatment and intensive monitoring followed by pre-emptive antiviral treatment are both commonly used management strategies to reduce risk of cytomegalovirus (CMV) infection following renal transplantation. This study employed a decision-model approach using published efficacy data and information from a recent survey of French clinical practice to consider the relative costs and outcomes associated with CMV prevention strategies for high-risk patient groups. The cost per case of treating tissue invasive and symptomatic CMV disease was estimated at \u20ac15,431 and \u20ac10,852, respectively. In the highest infection-risk patient group (positive donor with no previous CMV history) prophylactic oral valaciclovir was shown to avoid the greatest number of CMV disease cases (35 cases per 100 transplanted patients) and reduced the overall CMV-related costs per transplanted patient by around 14% over a \u2018wait-and-treat\u2019 baseline strategy. In contrast, intensive monitoring and pre-emptive treatment resulted in a much higher cost per transplanted patient. This analysis suggests that prophylactic treatment remains the most cost-effective approach to the management of CMV in renal-transplanted patients. Further comparative studies between prophylactic and pre-emptive treatment would be a valuable addition to the current evidence based on CMV prevention.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10198-004-0275-9", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1297512", 
        "issn": [
          "1439-3972", 
          "1439-6637"
        ], 
        "name": "The European Journal of Health Economics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "6"
      }
    ], 
    "keywords": [
      "pre-emptive treatment", 
      "renal transplantation", 
      "antiviral treatment", 
      "pre-emptive antiviral treatment", 
      "high-risk patient groups", 
      "CMV prevention strategies", 
      "symptomatic CMV disease", 
      "renal transplanted patients", 
      "management of cytomegalovirus", 
      "management of CMV", 
      "French clinical practice", 
      "intensive monitoring", 
      "CMV disease", 
      "oral valaciclovir", 
      "CMV prevention", 
      "cytomegalovirus infection", 
      "patient group", 
      "prophylactic treatment", 
      "efficacy data", 
      "current evidence", 
      "prevention strategies", 
      "clinical practice", 
      "disease cases", 
      "patients", 
      "further comparative studies", 
      "prophylaxis", 
      "valaciclovir", 
      "treatment", 
      "transplantation", 
      "decision model approach", 
      "valuable addition", 
      "CMV", 
      "cytomegalovirus", 
      "infection", 
      "greater number", 
      "disease", 
      "prevention", 
      "cost-effective approach", 
      "outcomes", 
      "management", 
      "risk", 
      "cases", 
      "tissue", 
      "study", 
      "management strategies", 
      "group", 
      "comparative study", 
      "monitoring", 
      "strategies", 
      "high cost", 
      "evidence", 
      "recent survey", 
      "contrast", 
      "relative costs", 
      "survey", 
      "practice", 
      "data", 
      "addition", 
      "number", 
      "analysis", 
      "cost", 
      "approach", 
      "information", 
      "baseline strategy"
    ], 
    "name": "The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation", 
    "pagination": "172-182", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1022923673"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10198-004-0275-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15765243"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10198-004-0275-9", 
      "https://app.dimensions.ai/details/publication/pub.1022923673"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_404.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10198-004-0275-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10198-004-0275-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10198-004-0275-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10198-004-0275-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10198-004-0275-9'


 

This table displays all metadata directly associated to this object as RDF triples.

233 TRIPLES      21 PREDICATES      102 URIs      92 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10198-004-0275-9 schema:about N0ce8d33aae2d487ca73c4533213cc643
2 N276156f428444d1ea0d90dedabc72e0e
3 N3e150e1599f74d458f1ca6af41638920
4 N53c26a044f164e85965e01351f763509
5 N67eb2d49319b4c119e177a7571ba96b7
6 N6b7ea8091e5f4f63a634f7f7b1c2e6be
7 N880357bf4e84469696487d772a8a8b55
8 N8d3b7149b9864d16b97ed21e4451a765
9 Ndc7d9850f16645d683bc909b81170219
10 Nf6b4c02cdc4c488bac25734b514a4816
11 anzsrc-for:11
12 anzsrc-for:1103
13 schema:author Nef560d47eb6143e79ddfabde42e90fda
14 schema:citation sg:pub.10.2165/00019053-200018030-00004
15 sg:pub.10.2165/00019053-200321070-00002
16 schema:datePublished 2005-06
17 schema:datePublishedReg 2005-06-01
18 schema:description Prophylaxis-based antiviral treatment and intensive monitoring followed by pre-emptive antiviral treatment are both commonly used management strategies to reduce risk of cytomegalovirus (CMV) infection following renal transplantation. This study employed a decision-model approach using published efficacy data and information from a recent survey of French clinical practice to consider the relative costs and outcomes associated with CMV prevention strategies for high-risk patient groups. The cost per case of treating tissue invasive and symptomatic CMV disease was estimated at €15,431 and €10,852, respectively. In the highest infection-risk patient group (positive donor with no previous CMV history) prophylactic oral valaciclovir was shown to avoid the greatest number of CMV disease cases (35 cases per 100 transplanted patients) and reduced the overall CMV-related costs per transplanted patient by around 14% over a ‘wait-and-treat’ baseline strategy. In contrast, intensive monitoring and pre-emptive treatment resulted in a much higher cost per transplanted patient. This analysis suggests that prophylactic treatment remains the most cost-effective approach to the management of CMV in renal-transplanted patients. Further comparative studies between prophylactic and pre-emptive treatment would be a valuable addition to the current evidence based on CMV prevention.
19 schema:genre article
20 schema:isAccessibleForFree false
21 schema:isPartOf N4573c14d8c99438c9b11e33da0f06154
22 Nc28aeab5adc849868a6a9118c564b691
23 sg:journal.1297512
24 schema:keywords CMV
25 CMV disease
26 CMV prevention
27 CMV prevention strategies
28 French clinical practice
29 addition
30 analysis
31 antiviral treatment
32 approach
33 baseline strategy
34 cases
35 clinical practice
36 comparative study
37 contrast
38 cost
39 cost-effective approach
40 current evidence
41 cytomegalovirus
42 cytomegalovirus infection
43 data
44 decision model approach
45 disease
46 disease cases
47 efficacy data
48 evidence
49 further comparative studies
50 greater number
51 group
52 high cost
53 high-risk patient groups
54 infection
55 information
56 intensive monitoring
57 management
58 management of CMV
59 management of cytomegalovirus
60 management strategies
61 monitoring
62 number
63 oral valaciclovir
64 outcomes
65 patient group
66 patients
67 practice
68 pre-emptive antiviral treatment
69 pre-emptive treatment
70 prevention
71 prevention strategies
72 prophylactic treatment
73 prophylaxis
74 recent survey
75 relative costs
76 renal transplantation
77 renal transplanted patients
78 risk
79 strategies
80 study
81 survey
82 symptomatic CMV disease
83 tissue
84 transplantation
85 treatment
86 valaciclovir
87 valuable addition
88 schema:name The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation
89 schema:pagination 172-182
90 schema:productId N1c9dfb17d8b545da9fbabd6b9ca72990
91 N484827e89cd049c7abeb98fae09164d3
92 Ne50a001c56a54087b88ba17ed1270b0e
93 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022923673
94 https://doi.org/10.1007/s10198-004-0275-9
95 schema:sdDatePublished 2022-12-01T06:25
96 schema:sdLicense https://scigraph.springernature.com/explorer/license/
97 schema:sdPublisher N3484643e364346bb9b168c27f83a158d
98 schema:url https://doi.org/10.1007/s10198-004-0275-9
99 sgo:license sg:explorer/license/
100 sgo:sdDataset articles
101 rdf:type schema:ScholarlyArticle
102 N0ce8d33aae2d487ca73c4533213cc643 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Immunocompromised Host
104 rdf:type schema:DefinedTerm
105 N10bc607c62a5462c95598799b26d8967 rdf:first sg:person.0677521431.14
106 rdf:rest N7e1df07355c84be5843bbf4ceff944a3
107 N1c9dfb17d8b545da9fbabd6b9ca72990 schema:name dimensions_id
108 schema:value pub.1022923673
109 rdf:type schema:PropertyValue
110 N276156f428444d1ea0d90dedabc72e0e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Cytomegalovirus
112 rdf:type schema:DefinedTerm
113 N3484643e364346bb9b168c27f83a158d schema:name Springer Nature - SN SciGraph project
114 rdf:type schema:Organization
115 N3e150e1599f74d458f1ca6af41638920 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Valine
117 rdf:type schema:DefinedTerm
118 N4573c14d8c99438c9b11e33da0f06154 schema:volumeNumber 6
119 rdf:type schema:PublicationVolume
120 N484827e89cd049c7abeb98fae09164d3 schema:name doi
121 schema:value 10.1007/s10198-004-0275-9
122 rdf:type schema:PropertyValue
123 N53c26a044f164e85965e01351f763509 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Cost-Benefit Analysis
125 rdf:type schema:DefinedTerm
126 N618efed589394e808770665a3cd8f3f9 rdf:first sg:person.01237500524.53
127 rdf:rest Nd84c7edf38cc48e2b649741ad6a5b576
128 N67eb2d49319b4c119e177a7571ba96b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Acyclovir
130 rdf:type schema:DefinedTerm
131 N6b7ea8091e5f4f63a634f7f7b1c2e6be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Kidney Transplantation
133 rdf:type schema:DefinedTerm
134 N7e1df07355c84be5843bbf4ceff944a3 rdf:first sg:person.01327533357.46
135 rdf:rest rdf:nil
136 N880357bf4e84469696487d772a8a8b55 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Humans
138 rdf:type schema:DefinedTerm
139 N8d3b7149b9864d16b97ed21e4451a765 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Cytomegalovirus Infections
141 rdf:type schema:DefinedTerm
142 Nc28aeab5adc849868a6a9118c564b691 schema:issueNumber 2
143 rdf:type schema:PublicationIssue
144 Nce34238a660d44659474d198a6ace471 rdf:first sg:person.01075026142.10
145 rdf:rest Nde6f54c908a14aad83b3498cf95e2188
146 Nd84c7edf38cc48e2b649741ad6a5b576 rdf:first sg:person.0626017540.31
147 rdf:rest Nce34238a660d44659474d198a6ace471
148 Ndc7d9850f16645d683bc909b81170219 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Antiviral Agents
150 rdf:type schema:DefinedTerm
151 Nde6f54c908a14aad83b3498cf95e2188 rdf:first sg:person.01217563561.87
152 rdf:rest N10bc607c62a5462c95598799b26d8967
153 Ne50a001c56a54087b88ba17ed1270b0e schema:name pubmed_id
154 schema:value 15765243
155 rdf:type schema:PropertyValue
156 Nef560d47eb6143e79ddfabde42e90fda rdf:first sg:person.07562422057.98
157 rdf:rest N618efed589394e808770665a3cd8f3f9
158 Nf6b4c02cdc4c488bac25734b514a4816 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Valacyclovir
160 rdf:type schema:DefinedTerm
161 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
162 schema:name Medical and Health Sciences
163 rdf:type schema:DefinedTerm
164 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
165 schema:name Clinical Sciences
166 rdf:type schema:DefinedTerm
167 sg:journal.1297512 schema:issn 1439-3972
168 1439-6637
169 schema:name The European Journal of Health Economics
170 schema:publisher Springer Nature
171 rdf:type schema:Periodical
172 sg:person.01075026142.10 schema:affiliation grid-institutes:grid.411777.3
173 schema:familyName Lebranchu
174 schema:givenName Yvon
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075026142.10
176 rdf:type schema:Person
177 sg:person.01217563561.87 schema:affiliation grid-institutes:grid.411430.3
178 schema:familyName Pouteil-Noble
179 schema:givenName Claire
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217563561.87
181 rdf:type schema:Person
182 sg:person.01237500524.53 schema:affiliation grid-institutes:None
183 schema:familyName Beard
184 schema:givenName Stephen M.
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237500524.53
186 rdf:type schema:Person
187 sg:person.01327533357.46 schema:affiliation grid-institutes:None
188 schema:familyName Durand-Zaleski
189 schema:givenName Isabelle
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327533357.46
191 rdf:type schema:Person
192 sg:person.0626017540.31 schema:affiliation grid-institutes:grid.476503.3
193 schema:familyName Crochard
194 schema:givenName Anne
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626017540.31
196 rdf:type schema:Person
197 sg:person.0677521431.14 schema:affiliation grid-institutes:grid.416262.5
198 schema:familyName Richter
199 schema:givenName Anke
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0677521431.14
201 rdf:type schema:Person
202 sg:person.07562422057.98 schema:affiliation grid-institutes:grid.413328.f
203 schema:familyName Legendre
204 schema:givenName Christophe
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07562422057.98
206 rdf:type schema:Person
207 sg:pub.10.2165/00019053-200018030-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028894956
208 https://doi.org/10.2165/00019053-200018030-00004
209 rdf:type schema:CreativeWork
210 sg:pub.10.2165/00019053-200321070-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008090922
211 https://doi.org/10.2165/00019053-200321070-00002
212 rdf:type schema:CreativeWork
213 grid-institutes:None schema:alternateName ANAES, St. Denis la Plaine, France
214 RTI Health Solutions, Williams House, Manchester Science Park, Lloyd Street North, M15 6SE, Manchester, UK
215 schema:name ANAES, St. Denis la Plaine, France
216 RTI Health Solutions, Manchester, UK
217 RTI Health Solutions, Williams House, Manchester Science Park, Lloyd Street North, M15 6SE, Manchester, UK
218 rdf:type schema:Organization
219 grid-institutes:grid.411430.3 schema:alternateName Lyon-Sud Hospital, Pierre-Benite, France
220 schema:name Lyon-Sud Hospital, Pierre-Benite, France
221 rdf:type schema:Organization
222 grid-institutes:grid.411777.3 schema:alternateName Bretonneau Hospital, Tours, France
223 schema:name Bretonneau Hospital, Tours, France
224 rdf:type schema:Organization
225 grid-institutes:grid.413328.f schema:alternateName St. Louis Hospital, Paris, France
226 schema:name St. Louis Hospital, Paris, France
227 rdf:type schema:Organization
228 grid-institutes:grid.416262.5 schema:alternateName RTI Health Solutions, Research Triangle Park, N.C., USA
229 schema:name RTI Health Solutions, Research Triangle Park, N.C., USA
230 rdf:type schema:Organization
231 grid-institutes:grid.476503.3 schema:alternateName GlaxoSmithKline, Marly le Roi, France
232 schema:name GlaxoSmithKline, Marly le Roi, France
233 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...